Literature DB >> 17294439

The electromyographic diagnosis of amyotrophic lateral sclerosis: does the evidence support the El Escorial criteria?

Achraf A Makki1, Michael Benatar.   

Abstract

The aim of this retrospective cohort study was to examine the accuracy of the El Escorial electromyographic criteria for the diagnosis of amyotrophic lateral sclerosis (ALS). Based on a consecutive series of 73 patients with suspected ALS, the sensitivity of electromyography (EMG) ranged from 0.2 in the cranial segment to 0.74 in the thoracic segment. Specificity was highest (0.92-1.0) in the cranial and thoracic segments. Using receiver operating characteristic (ROC) curve analysis to examine the effect of varying the number of abnormal segments required for the diagnosis, we found an overall accuracy of 0.90 and 0.87 if one or two abnormal segments, respectively, were required. The best combination of sensitivity and specificity was achieved by requiring EMG changes in two segments with abnormalities in a single muscle in the cranial and thoracic segments, but abnormalities in two muscles in the cervical and lumbosacral regions. These findings lend support to the EMG criteria proposed at El Escorial.

Entities:  

Mesh:

Year:  2007        PMID: 17294439     DOI: 10.1002/mus.20748

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Prediction of prognosis of ALS: Importance of active denervation findings of the cervical-upper limb area and trunk area.

Authors:  Yoko Sato; Eiji Nakatani; Yasuhiro Watanabe; Masanori Fukushima; Kenji Nakashima; Mari Kannagi; Yasuhiro Kanatani; Hiroshi Mizushima
Journal:  Intractable Rare Dis Res       Date:  2015-11

2.  CSF neurofilament protein analysis in the differential diagnosis of ALS.

Authors:  Thierry S Reijn; Wilson F Abdo; Helenius J Schelhaas; Marcel M Verbeek
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

3.  An improved electrical impedance myography (EIM) tongue array for use in clinical trials.

Authors:  Courtney McIlduff; Sung Yim; Adam Pacheck; Tom Geisbush; Aleksandar Mijailovic; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2015-07-02       Impact factor: 3.708

Review 4.  Amyotrophic lateral sclerosis: a focus on disease progression.

Authors:  Ana C Calvo; Raquel Manzano; Deise M F Mendonça; María J Muñoz; Pilar Zaragoza; Rosario Osta
Journal:  Biomed Res Int       Date:  2014-08-03       Impact factor: 3.411

5.  Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.

Authors:  Michael Benatar; Joanne Wuu; Caroline McHutchison; Ronald B Postuma; Bradley F Boeve; Ronald Petersen; Christopher A Ross; Howard Rosen; Jalayne J Arias; Stephanie Fradette; Michael P McDermott; Jeremy Shefner; Christine Stanislaw; Sharon Abrahams; Stephanie Cosentino; Peter M Andersen; Richard S Finkel; Volkan Granit; Anne-Laure Grignon; Jonathan D Rohrer; Corey T McMillan; Murray Grossman; Ammar Al-Chalabi; Martin R Turner
Journal:  Brain       Date:  2022-03-29       Impact factor: 15.255

6.  Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype.

Authors:  Stefano Zoccolella; Antonella Mastronardi; Antonio Scarafino; Giovanni Iliceto; Eustachio D'Errico; Angela Fraddosio; Irene Tempesta; Antonella Morea; Gaspare Scaglione; Alessandro Introna; Isabella Laura Simone
Journal:  J Neurol       Date:  2020-07-16       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.